?This approval is based on the results from a multi-center, open-label, uncontrolled Phase I/II study (ONO-4059-02), conducted in
This approval represents that Velexbru is the first BTK inhibitor approved in
About ONO-4059-02 Study
This study is a multi-center, open-label, uncontrolled Phase I/II study, evaluating the efficacy and safety of Velexbru monotherapy in patients with recurrent or refractory PCNSL. In this study, 44 patients were recruited and received Velexbru 320 mg (20 patients), 480 mg (7 patients) and 480 mg fasted (17 patients), orally, once a day in each group. Patients were treated until disease progression or unacceptable toxicity was observed. The primary endpoint of this study is ORR assessed by the IRC.
About Primary Central Nervous System Lymphoma (PCNSL)
PCNSL is a malignant lymphoma in which the lesion is localized in the cerebrospinal cord (including the eyes) at the first onset. The signs and symptoms presented by patients with PCNSL vary depending on the site of the lesion, and include localized neuropathy, neuropsychiatric symptoms, symptoms associated with increased intracranial pressure, seizure, eye symptoms, headache, difficulty in movement, cranial neuropathy and radiculopathy.
Currently, untreated PCNSL patients receive high-dose methotrexate-based treatment followed by whole-brain radiation therapy, by which a certain patient population shows long-term remissions, but many patients will relapse. There are also refractory patients who do not respond to the drug treatment. Standard treatment has not been established for patients with recurrent or refractory PCNSL, and treatment options are limited for them. Therefore, a new treatment drug is expected for this patient population.
About Velexbru
Velexbru is a highly selective, oral Bruton's tyrosine kinase (BTK) inhibitor. B-cell receptor (BCR) signaling plays a core role in the survival, activation, proliferation, maturation and differentiation of B-cell lymphocyte. The BCR signaling pathway is known to be permanently activated, particularly in B-cell non-Hodgkin lymphoma (B-NHL) and chronic lymphocytic leukemia (CLL). Velexbru is expected to have a therapeutic effect because it inhibits BTK, a mediator located downstream of BCR.
In
Outside of the oncology field, ONO is conducting clinical studies for the treatment of pemphigus (Phase II) and generalized scleroderma (Phase I).
About
Contact:
Corporate Communications
E: public_relations@ono.co.jp
(C) 2021 Electronic News Publishing, source